Literature DB >> 25933544

Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.

Xiaole Qi1, Yuchao Fan1, Huan He1, Zhenghong Wu2.   

Abstract

Herein, we developed dualfunctional hyaluronic acid (HA)-grafted polyamidoamine (PAMAM) dendrimers for simultaneous systemic long circulation and active tumor targeting and delivery of topotecan hydrochloride (TPT). The possibility of these modified dendrimers as nanocarriers for promoting tissue distribution and antitumor efficiency, as well as a drug release profile, cytotoxicity and cellular uptake, was investigated. The fine targeting efficiency of HA-PAMAM/TPT was confirmed by the CD44 receptor-mediated high cellular uptake efficiency and low cytotoxicity in HCT-116 cells, and the in vivo higher tumor distribution percentage than in other tissues in mice bearing an S-180 tumor. Pharmacokinetic studies showed that the t1/2 and MRT of TPT were significantly extended after intravenous administration of HA-PAMAM/TPT in normal rats. Moreover, TPT-loaded nanovehicles demonstrated higher antitumor activity compared with free drug and PAMAM/TPT. Overall, HA-PAMAM may be an alternative vector for the effective targeted delivery of and tumor therapy with antitumor drugs.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hyaluronic acid; Nanoparticles; Polyamidoamine dendrimers; Topotecan hydrochloride; Tumor targeting; Tumor therapy

Mesh:

Substances:

Year:  2015        PMID: 25933544     DOI: 10.1016/j.carbpol.2015.03.019

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  9 in total

Review 1.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

Review 2.  Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review.

Authors:  Nader Salari; Kamran Mansouri; Elahe Valipour; Farzaneh Abam; Mehdi Jaymand; Shna Rasoulpoor; Sadat Dokaneheifard; Masoud Mohammadi
Journal:  Daru       Date:  2021-09-09       Impact factor: 4.088

Review 3.  Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.

Authors:  Erika Dosekova; Jaroslav Filip; Tomas Bertok; Peter Both; Peter Kasak; Jan Tkac
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

4.  Hyaluronic acid-modified didecyldimethylammonium bromide/ d-a-tocopheryl polyethylene glycol succinate mixed micelles for delivery of baohuoside I against non-small cell lung cancer: in vitro and in vivo evaluation.

Authors:  Hongmei Yan; Jie Song; Xiaobin Jia; Zhenhai Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.

Authors:  Xin Zhang; Jiayi Pan; Momei Yao; Livia Palmerston Mendes; Can Sarisozen; Shirui Mao; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2020-07-06       Impact factor: 5.589

Review 6.  Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses.

Authors:  Panoraia I Siafaka; Neslihan Üstündağ Okur; Evangelos Karavas; Dimitrios N Bikiaris
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

7.  Specific cancer stem cell-therapy by albumin nanoparticles functionalized with CD44-mediated targeting.

Authors:  Yuanyuan Li; Sanjun Shi; Yue Ming; Linli Wang; Chenwen Li; Minghe Luo; Ziwei Li; Bin Li; Jianhong Chen
Journal:  J Nanobiotechnology       Date:  2018-12-01       Impact factor: 10.435

Review 8.  Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review.

Authors:  Nadda Muhamad; Tullayakorn Plengsuriyakarn; Kesara Na-Bangchang
Journal:  Int J Nanomedicine       Date:  2018-07-04

Review 9.  Current Trends in ATRA Delivery for Cancer Therapy.

Authors:  Maria Valeria Giuli; Patrizia Nadia Hanieh; Eugenia Giuliani; Federica Rinaldi; Carlotta Marianecci; Isabella Screpanti; Saula Checquolo; Maria Carafa
Journal:  Pharmaceutics       Date:  2020-07-28       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.